BioWorld Asia

Aug. 9, 2006

Paion Accelerates Phase III Program For Desmoteplase

Paion AG is accelerating the Phase III development program for its lead compound, the recombinant plasminogen activator Desmoteplase, which is in development for treating acute ischemic stroke. (BioWorld International) Read More

Serum Institute Invests In Lipoxen; Firms Sign Deal

Neutralizing Antibody Has Promise Versus HIV Strains

Biosecurity Rises Higher Up On Europe's Agenda

Chasing Next-Generation Stents, Axordia Working With Lombard

After Knocking Out Genes, Rye Grass Pollen Made Sneeze-Free

Immutep Initiating Phase I IMP321 Breast Cancer Trial

Diamyd Medical Enters First GAD65 Out-Licensing Deal

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 17, 2026.

Man holding raised arm with illustrated overlay of nerves

Biohaven reports details on discovery of BHV-2100

BioWorld Science

Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...

New GABA(B) receptor PAMs revealed in Addex Pharma patents

BioWorld Science

Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...

Elderly woman holding illustration of brain with missing puzzle piece

Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

BioWorld

The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...

Novel caspase-2 inhibitor shows in vivo neuroprotective effects

BioWorld Science

Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...